LDS/Medical Tests/Hepatitis B Virus (HBV) by Molecular Method, Quantitative (Viral Load)

Hepatitis B Virus (HBV) by Molecular Method, Quantitative (Viral Load)

Hepatitis B virus (HBV) belongs to DNA Hepadnaviridae family. It is a major causative agent of chronic hepatitis and can cause liver cirrhosis and hepatocellular carcinoma. Based on genetic differences eight HBV subgroups (A-H) have been recognized. Genotype A is most common in the United States. Over two billion people throughout the world have been infected with HBV and over 350 million of them are chronically infected carriers. HBV is spread through contact with blood or other body fluids from an infected person. Exposure can occur, for example, through sharing of needles for intravenous (IV) drug use or through unprotected sexual intercourse. Mothers can pass the infection to their babies, usually during or after birth. The virus is not spread through food or water, casual contact such as holding hands, or coughing or sneezing. Effective vaccines for hepatitis B virus have been available since 1982 and infant and childhood vaccination programs introduced in the 1990s have resulted in a marked decrease in new infections. The HBV symptoms can vary from a mild form of infection that lasts only a few weeks to a more serious chronic infection that might last years. A smaller percentage progress to chronic HBV infection that may lead to serious complications such as cirrhosis or liver cancer. Based on the symptoms and complications, hepatitis B infection can be staged as:

  • Acute infection; characterized by the presence of typical hepatitis signs and symptoms with positive screening test for hepatitis B virus. 15-30% of acute infections progress to chronic HBV infection.
  • Chronic infection; characterized by mild symptoms. Chronic disease is a a persistent infection with the virus detected by lab tests and is manifested by inflammation of the liver. Hepatitis B surface antigen (HBsAg) is positive longer than 6 months for this stage. Hepatitis B e antigen (HBeAg) is positive and indicates viral proliferation. Viral loads range from 3 logs to 6 logs dependent upon the patient’s immune status.
  • Carrier (inactive) state, characterized with a persistent infection but with no liver inflammation. Usually carriers may not show symptoms and appear to be in good health but harbor the virus and can potentially infect others. In this state HBeAg becomes negative, hepatitis B e antibody (anti-HBe) appears (seroconversion), and transaminase levels normalize; however, low level of HBV DNA still may be present.
  • "Cleared" infection stage, when infected patients no longer have any evidence of infection. These patients test negative for viral antigen and viral DNA and show no signs or symptoms of liver inflammation. However, in some cases, these patients might still have virus in the latent form or in an inactive state in the liver.

The signs and the symptoms of an acute hepatitis B infection can be very similar to those of other types of acute hepatitis. The classic signs and symptoms include fever, tiredness, nausea, vomiting, and jaundice. If infection persists longer and results in hepatitis (liver inflammation), it can cause liver damage which may result in cirrhosis, characterized serologically by an increase in bilirubin and liver enzymes and pathologically by liver fibrosis.

It is important to mention that chronic carriers are at high risk for long-term complications of infection, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The ability to detect HBV DNA in serum has been reported to have prognostic value for the outcome of acute and chronic HBV infections. The methodology can allow the detection of HBV DNA after HBsAg clearance or detection of HBV in patients lacking serologic marker abnormality. However, a relationship between serologic markers and HBV DNA levels has not yet been established. Although the efficacy of antiviral therapy used to treat patients with HBV can also be assessed by serologic markers or by measurement of liver enzyme function, the most direct and reliable measurement of viral replication is thought to be quantitation of HBV viral DNA in serum or plasma. A rapid and sustained drop in HBV DNA levels in patients receiving treatment with alpha-interferon, lamivudine, entecavir, telbivudine, and peginterferon alpha-2a has been shown to be associated with a favorable treatment outcome. Monitoring of HBV DNA levels can predict the development of resistance to lamivudine. Therefore, a quantitative test for the measurement of HBV DNA is a valuable tool that can be used in conjunction with other clinical and laboratory findings in the management of HBV infection.

High levels of HBV-DNA, which can reach up to millions or billions of international units per milliliter (IU/mL) indicate rapid viral replication in the liver and a higher risk of liver damage. Low or undetectable rates indicate low viral replication in the liver. Because viral loads can be very high, viral load can be reported in a logarithmic form (base 10).

  • Diagnosis of HBV infection
  • Confirmation of HBV infection
  • Treatment adjustment and monitoring
  • Disease management
  • Blood/tissue donor testing

Positive in:

  • Acute hepatitis B infection, chronic hepatitis B, HBV carriers

Not Detected

 

Real-Time polymerase chain reaction (PCR), Transcription mediated amplification (TMA). 

Serum (SST), Plasma ACD (Yellow), PPT (White). 

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Comprehensive Metabolic Panel, Liver Panel, Liver Enzymes, Acute Hepatitis Profile that includes Hepatitis A Antibody, HBV Antigens and Antibody, Hepatitis C Antibody, HBV Genotyping, HBV Phenotyping.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login